Fujifilm Biotechnologies inaugurated an expanded Teesside site in the UK, unveiling what the company calls the largest single‑use biopharmaceutical CDMO facility in the country. Fujifilm Corp. funded approximately £400 million ($545 million) for the expansion, which adds 2,000 L and 5,000 L single‑use bioreactors and a Bioprocess Innovation Centre (BIC UK). The site will be operational in the first half of 2026 and integrates Fujifilm’s kojoX modular approach for rapid technology transfer across its global network. Company executives, including Toshihisa Iida, framed the expansion as a capacity and process‑development play to support antibody manufacturing and complex biologics for oncology, neurodegeneration and rare diseases. The investment aims to increase supply‑chain agility for pharma partners and accelerate process development through high‑throughput and continuous processing laboratories. Single‑use CDMO facilities use disposable bioreactors and consumables to reduce cross‑contamination risk and speed campaign changeovers.